$385 Million is the total value of MPM BioImpact LLC's 33 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 31.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INBX | Buy | Inhibrx, Inc Com | $31,697,758 | +38.0% | 1,286,435 | +0.5% | 8.22% | +51.1% |
| ISEE | Buy | Iveric Bio Inc | $22,687,920 | +20.4% | 1,059,688 | +0.9% | 5.89% | +31.9% |
| QURE | New | Uniqure N.V. | $21,309,029 | – | 939,966 | +100.0% | 5.53% | – |
| GERN | Buy | Geron Corporation | $20,490,094 | +4.0% | 8,466,981 | +0.5% | 5.32% | +13.9% |
| NTLA | Buy | Intellia Therapeutics, Inc. | $15,883,254 | -24.2% | 455,238 | +21.6% | 4.12% | -16.9% |
| VERV | Buy | Verve Therapeutics, Inc | $15,647,590 | -28.4% | 808,661 | +27.2% | 4.06% | -21.5% |
| RGNX | Buy | REGENXBIO Inc. | $14,092,717 | -13.9% | 621,372 | +0.4% | 3.66% | -5.7% |
| IOVA | Buy | Iovance Biotherapeutics Inc Com | $13,735,625 | -15.7% | 2,149,550 | +26.4% | 3.56% | -7.6% |
| PRVB | Buy | Provention Bio Inc | $9,496,965 | +185.0% | 898,483 | +21.4% | 2.46% | +212.3% |
| INSM | New | Insmed Incorporated | $8,201,051 | – | 410,463 | +100.0% | 2.13% | – |
| HRMY | Buy | Harmony Biosciences Hldgs Inc. | $7,679,673 | +26.8% | 139,377 | +1.9% | 1.99% | +38.8% |
| RETA | Buy | Reata Pharmaceuticals inc-a | $7,376,936 | +63.9% | 194,181 | +8.4% | 1.91% | +79.5% |
| CRNX | Buy | Crinetics Pharmaceuticals Inc. | $6,800,994 | -5.1% | 371,639 | +1.9% | 1.76% | +4.0% |
| TVTX | Buy | Travere Therapeutics Inc. | $5,924,382 | -13.0% | 281,711 | +1.9% | 1.54% | -4.7% |
| FOLD | Buy | Amicus Therapeutics Inc. | $4,889,006 | +19.2% | 400,410 | +1.9% | 1.27% | +30.5% |
| AXSM | New | Axsome Therapeutics, Inc. | $4,008,832 | – | 51,975 | +100.0% | 1.04% | – |
| ARQT | Buy | Arcutis Biotherapeutics inc | $3,878,621 | -21.1% | 262,069 | +1.9% | 1.01% | -13.6% |
| RVMD | Buy | Revolution Medicines, Inc. | $3,550,204 | +23.3% | 149,043 | +2.1% | 0.92% | +35.0% |
| PHAT | Buy | Phathom Pharmaceuticals inc | $2,198,469 | +2.6% | 195,942 | +1.4% | 0.57% | +12.4% |
| KDNY | New | Chinook Therapeutics, Inc. | $2,096,000 | – | 80,000 | +100.0% | 0.54% | – |
| PRAX | New | Praxis Precision Medicines Inc. | $1,451,800 | – | 610,000 | +100.0% | 0.38% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
| Repare Therapeutics, Inc. | 14 | Q3 2023 | 19.7% |
| TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
| iTeos Therapeutics, Inc. | 13 | Q3 2023 | 15.7% |
| G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
| Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
| Cullinan Oncology, Inc. | 11 | Q3 2023 | 41.4% |
| Epizyme, Inc. | 11 | Q2 2022 | 22.1% |
| Oncorus, Inc. | 11 | Q2 2023 | 13.3% |
| Intellia Therapeutics, Inc. | 10 | Q3 2023 | 5.5% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| SC 13D/A | 2023-08-01 |
| SC 13D | 2023-06-12 |
| 4 | 2023-06-05 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-11 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.